Introduction
Modern approaches to cancer therapeutic development are becoming increasingly selective, sometimes targeting single inter-molecular interactions or mutated oncoproteins, allowing for dramatic efficacy in defined subsets of patients with specific genetic abnormalities. This is the case for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, in the setting of exon 19 deleted or L858R point mutated lung cancer tumors (1, 2) . However, responses to TKIs are often short-lived and have failed to result in cures, alone or in combinations, in the metastatic setting. TKIs have also failed to improve survival after curative-intent therapy of early stage disease. For example, one clinical trial, SWOG 0023, randomized stage III patients to gefitinib therapy or placebo after curative-intent chemotherapy and radiation (3) . Surprisingly, the study had to be stopped because the overall survival was significantly worse in the arm treated with the kinase inhibitor, unrelated to drug toxicity. In earlier stage tumors, stages I and II, where complete surgical resection results in cures in more than half of patients, addition of gefitinib after surgery might be expected to dramatically improve survival, particularly in patients with EGFR mutated tumors. However, gefitinib failed to increase either PFS or OS, with a strong trend toward worsened overall survival with a hazard ratio of 1.2 in the entire group (4) . The group with the largest expected apparent after the cessation of inhibitor therapy. We set out to test these hypotheses in this study. Notch receptors are highly conserved, single pass type I transmembrane proteins known to play a role in cell proliferation, cell death and differentiation (5) . They have also been linked to multiple human disorders including cancers where different Notch family members are implicated as oncogenes or tumor suppressor genes in different settings (6) (7) (8) . In lung cancers, Notch was originally implicated in an epithelial tumor by the discovery of a chromosome translocation causing massive overexpression of Notch3 (9) and subsequently Notch receptors and ligands have been found to be overexpressed in a majority of solid tumors, including non-small cell lung cancer (NSCLC) (9, 10).
Transgenic mice overexpressing an activated Notch3 in the bronchial epithelium showed perinatal lethality due to arrested differentiation of type II progenitors, and the absence of type I pneumocytes (11).
More recently, multiple studies have shown the Notch pathway to be important in stem cell biology (12-15). Notch has also been shown to play a role in cancer stem cells in many tumor types, including breast, brain, and lung cancer (16) (17) (18) (19) . In breast ductal carcinoma in situ (DCIS), formation of mammospheres, an indicator of stem-like cells, is decreased upon treatment with Notch inhibitors (18, 20, 21).
In lung cancer, ALDH positivity has been convincingly associated with stem-like cell characteristics and inhibition of Notch3 abrogated the colony and tumor-forming ability of ALDH-positive cells (15, 19) . High expression of ALDH1 by immunohistochemistry was also associated with a worsened survival after curative-intent In the present study, we sought to determine if Notch signaling could be enhanced by EGFR inhibition resulting in differential effects on the stem-like cell population of human lung cancer cells with mutated or wild type EGFR. We found that while inhibition of EGFR leads to a dramatic reduction of tumor cell numbers, it also leads to a potent activation of the Notch pathway with an increase in the relative abundance of ALDH+ stem-like cells in a Notch3-dependent fashion and an increase in the clonogenicity as determined by spheroid assay. Combined inhibition of EGFR and Notch3 receptors substantially reduces the expansion of stem-like cells. This is the first report showing erlotinib treatment activates Notch in human lung cancer, resulting in an enriched stemlike populations in a Notch3-, and not Notch1-dependent manner. Additionally, this is also the first study to demonstrate kinase-dependent complex formation of these two receptors leading to the tyrosine phosphorylation of Notch3 in human lung cancer cells.
Research. 
Pulmosphere formation assay
To study the stem-like cell phenotype, sphere formation assays were performed as described previously (25) with modifications. HCC827 cells treated with vehicle control or erlotinib were trypsinized and counted using Luna automated cell counter. Cells were seeded in 96-well plates at 1000 cells per well in RPMI supplemented with 10% fetal bovine serum, 35 μg/ml bovine pituitary extract (Life Technologies), N2 supplement (Invitrogen), 20 ng/ml EGF, 20 ng/m (Life Technologies), basic fibroblast growth factor (Roche) and 50% Geltrex LDEV-free, hESC-qualified, reduced growth factor basement membrane matrix (Geltrex) (Life Technologies). Cells containing the semi solid medium were seeded in triplicate. The culture was allowed to solidify at 37 0 C for 30 min followed by layering of 200 μl of similar growth medium without 50% geltrex and incubated for one to 3 weeks. Pulmosphere number was determined using the GelCount mammalian cell colony counter (Oxford Optronix).
Soft agar assay
To measure in vitro tumorigenicity due to erlotinib treatment treated and untreated H358 cells at a density of 10,000 cells per well in 6-well plate were plated in soft agar, in triplicate. The assay was performed using 0.5% and 0.35% agar in RPMI1640 supplemented with 10% FBS as the base and top layers, respectively. Cells were incubated for 21 days and medium was refreshed twice per week. Colonies were counted using GelCount (Oxford Optronix). The colony efficiency was calculated as proportion of colonies per total number of seeded cells. The data was analyzed using GelCount software.
Results

Pharmacological inhibition of EGFR increases the fraction of ALDH+ cells in lung cancer cell lines
We tested whether there is a relationship between EGFR inhibition and the fraction and number of stem-like cells in NSCLC cell lines. EGFR mutated lung adenocarcinoma cells were treated with DMSO or 0.1 µM erlotinib and the medium was changed every day with fresh drug. Equal numbers of cells were subjected to ALDH enzymatic activity assays with the ALDH+ and ALDH-cell populations quantified using flow cytometry. We found that HCC4006 and HCC827 NSCLC cell lines, each with an EGFR activating mutation (EGFR ∆E746-A750) ( Fig. 1a and b) , showed dramatic increases in the fraction of ALDH+ cells upon treatment with erlotinib compared to DMSO treated cells (Table 1) . Interestingly, for HCC4006 cells, which have very low basal ALDH activity, while treatment with erlotinib killed much of the ALDHpopulation, it appeared to maintain or even increase the total number of ALDH+ cells by a small percentage. However, unlike HCC4006 cells, HCC827 cells appear to have a large fraction of cells with low to moderate baseline ALDH activity (3.5% for HCC4006 vs 17.7% for HCC827). This basal activity may not accurately reflect the stem-like cell population. When the analysis is based on those cells with the highest ALDH activity, by gating on the DMSO treated cells without DEAB, the total number of ALDH+ cells with very high activity increased in the HCC827 cells from 491,200 to 782,100 (Supplementary Fig. 1A and 1B; Supplementary Table 1) . This demonstrates that while erlotinib treatment causes a large reduction in the total cell numbers for each cell lines, the total number of ALDH high+ cells is increased. Supplementary Fig. 1a and We further wanted to explore if this phenomenon was also present in H1650 cells, which are also EGFR mutant but resistant to erlotinib due to loss of PTEN (27).
Interestingly, erlotinib treatment also had no effect on the ALDH populations in these cells ( Supplementary Fig. 2 ). Additional studies with A549 and H358 cells carrying wild type EGFR and a K-RAS mutation (28) ( Supplementary Fig. 3a and b) also showed increased ALDH activity upon exposure to erlotinib. Unlike H1650, which are completely insensitive to erlotinib, the H358 cell line and A549 cell line are somewhat sensitive to erlotinib (H358 more so than A549) (29) and also show increases in the fraction of ALDH+ cells with erlotinib treatment. These data suggest that this phenomenon is not just restricted to cells with an EGFR activating mutation, but limited to those with some EGFR-signaling dependence, and that EGFR activity is coupled with ALDH activity. the pulmospheres in semisolid matrix ( Fig. 2a and b) . We also performed a soft agar colony formation assay, which measures anchorage-independent growth and is an indicator for cell transformation using H358 cells. Cells treated with erlotinib showed significant increase in number of colonies formed compared to DMSO control ( Fig. 2c and d). These data clearly suggest that erlotinib treatment increases the clonogenic potential in the surviving population of cells.
EGFR signaling down-regulates Notch-mediated transcriptional activity in a kinasedependent manner
To assess if the erlotinib-mediated stem-like cell phenotype is due to modulation of transcriptional activity of Notch, we examined the Notch transcriptional activity in the presence of wild type-or kinase inactive-EGFR. HEK293 cells were transiently transfected with EGFR and Notch3-ICD along with Notch inducible CSL-synthetic- (Fig.   3a ) or full-length Hes1 promoter-driven luciferase reporters (Fig. 3b) . Two days after transfection transcriptional activity was measured using a luciferase assay. The coexpression of EGFR with Notch3-ICD decreased Notch3-ICD-mediated CSL and Hes1 reporter activities in a dose-dependent manner. We further determined if kinase activity is essential for EGFR-mediated negative regulation of Notch3. Notch3-ICD was coexpressed with a kinase-inactive mutant of EGFR and co-expression of this kinaseinactive EGFR did not result in a decrease in Notch-mediated transcriptional activity, demonstrating that EGFR negatively regulates Notch activity through its tyrosine kinase activity. Interestingly, there was a slight increase in reporter activity compared to baseline when EGFR (KD) was transfected Fig. 3A and 3B ), which may have been due to interference with endogenous EGFR activity. To make certain that the EGFR transfection The qRT-PCR analysis of Hes1 expression showed a significant increase after 24 or 48 hours of treatment with erlotinib in HCC827 cells (Fig. 3c) . This demonstrates EGFR kinase activity inhibits Notch signaling, and thus erlotinib treatment relieves this inhibition resulting in Notch transcriptional activation.
Gamma secretase inhibitor treatment eliminates erlotinib-induced stem-like cells by decreasing Notch activity
The major Notch pathway inhibitors in clinical testing are gamma secretase and in which the combination of Notch and EGFR-targeted therapies show an increased efficacy (10, 31). Cells were stimulated with EGF for increasing amounts of time and total EGFR was precipitated, and blotted for Notch3. These analyses identified clear EGF-dependent co-precipitation of Notch3 with EGFR (Fig. 6a) . In the absence of ligand, little or no association was observed between EGFR and Notch receptors, indicating that the association is ligand (EGF)-dependent. To further validate the interaction between EGFR and Notch3, co-immunoprecipitations were performed using three different antibodies that target distinct epitopes on the EGFR protein. Western blot analyses showed that Notch3 co-immunoprecipitates with all three EGFR antibodies, and this association was further enhanced when stimulated with EGF ( Supplementary Fig. 6 ).
We further tested if the association between EGFR and Notch receptor is dependent on the kinase activity of EGFR. HCC4006 and HCC827 cells expressing constitutively active EGFR were treated with vehicle control or erlotinib and subjected to co-immunoprecipitation. As expected, control cells showed strong interaction between Notch and EGFR, and erlotinib treatment completely abolished this interaction ( Fig. 6b and c). Reciprocal immunoprecipitation revealed the same result ( Fig. 6b and c ). These experiments demonstrate that EGFR associates with Notch3 receptor in a kinasedependent fashion.
EGFR mediated tyrosine phosphorylation of Notch receptors
Little is known about post-translational modifications of the Notch receptor and their role in regulating Notch activity (32). The co-immunoprecipitation and functional associations above led us to speculate that Notch3 could be a novel direct or indirect substrate for EGFR mediated tyrosine phosphorylation, which may mediate its role as a negative regulator. To demonstrate tyrosine phosphorylation of the Notch receptor, HCC2429 cells that overexpress Notch3 due to translocation, and wild-type EGFR were stimulated with EGF for increasing durations of exposure. Total protein lysates were immunoprecipitated with a Notch3 antibody and analyzed with either phosphotyrosine or Notch3 antibody (Fig. 7a) or immunoprecipitated with phosphotyrosine and subjected to western analysis with Notch3 (Fig. 7b) . These data clearly show that following the addition of EGF, Notch3 is phosphorylated in a time-dependent manner. These data are the first to demonstrate tyrosine phosphorylation of Notch and to identify Notch as a novel direct or indirect substrate for the EGFR tyrosine kinase.
To confirm that the observed tyrosine phosphorylation of Notch3 is dependent on EGFR kinase activity, cells were treated with vehicle or erlotinib for 1 or 24 hours.
Treatment with erlotinib reduced the tyrosine phosphorylation of Notch3 in a timedependent manner ( Fig. 8a and b) . Furthermore, the phosphorylation was detected reciprocally, demonstrating that Notch3 phosphorylation is due to EGFR kinase activation. A similar pattern was observed for tyrosine-1173 auto phosphorylation of EGFR, further confirming that the Notch3 receptor is tyrosine phosphorylated in an EGFR kinase-dependent fashion.
To further address if EGFR mediated Notch3 tyrosine phosphorylation is indeed a key regulatory event that modulates the stem-like phenotype in lung cancer cells we used H1650 cells, which do not show an increase in ALDH activity in response to erlotinib treatment ( Supplementary Fig. 2) , and also show a continuously active EGFR in the presence of erlotinib (Supplementary Fig. 7 ). Phosphotyrosine analysis of Notch3 In lung cancer, ALDH positivity has been found to be a good marker for a tumor cell subset with stem-like cell properties and this subset is dependent on Notch3 for clonogenicity and tumorigenic potential (19). In the present study, we document a reciprocal activation of EGFR and Notch in human lung cancer, and thus a previously We show here that EGFR directly modulates Notch activity in human lung cancers, and that there is a kinase dependent physical association of the two receptors. either precipitated with a phosphotyrosine antibody followed by a western blot probed with Notch3 antibody (top), or immunoprecipitated with Notch3 antibody followed by a western blot probed with a phosphotyrosine antibody. Whole cell lysate was also subjected to western analysis to check for of levels Notch3, EGFR-pY1173, and tubulin. 
